|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 38/26 | (2006.01) |
| A61P 3/10 | (2006.01) |
| (11) | Number of the document | 2991671 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14721834.1 |
| Date of filing the European patent application | 2014-05-02 | |
| (97) | Date of publication of the European application | 2016-03-09 |
| (45) | Date of publication and mention of the grant of the patent | 2018-08-15 |
| (46) | Date of publication of the claims translation | 2018-09-25 |
| (86) | Number | PCT/EP2014/058974 |
| Date | 2014-05-02 |
| (87) | Number | WO 2014/177683 |
| Date | 2014-11-06 |
| (30) | Number | Date | Country code |
| 13166205 | 2013-05-02 | EP |
| (72) |
NIELSEN, Flemming Seier, DK
SAUERBERG, Per, DK
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Geriami GLP-1 junginiai |
| ORAL DOSING OF GLP-1 COMPOUNDS |
| Payment date | Validity (years) | Amount | |
| 2023-04-20 | 10 | 231.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2023-12-05 |